Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Sep 8;17(3 Suppl 2):19154.
doi: 10.7448/IAS.17.3.19154. eCollection 2014.

ARV-based HIV prevention for women - where we are in 2014

Timothy D Mastro  1 , Nirupama Sista  2 , Quarraisha Abdool-Karim  3
Affiliations
Review

ARV-based HIV prevention for women - where we are in 2014

Timothy D Mastro et al. J Int AIDS Soc. .

Abstract

Women continue to be at special risk for HIV acquisition due to a complex mix of biological, behavioural, structural, cultural and social factors, with unacceptable rates of new infection. Scientific advances over the past decade have highlighted the use of antiretroviral (ARV) drugs as pre-exposure prophylaxis (PrEP) to prevent HIV acquisition (sexually, parenterally and vertically) and ARV treatment (ART) for HIV-positive patients to prevent onward transmission (treatment as prevention - TasP). This paper reviews the evidence base for PrEP and TasP, describes new products in development and the need to translate research findings into programmes with impact at the population level.

Keywords: AIDS; HIV; HIV prevention; HIV treatment; PrEP; antiretroviral agents; women.

PubMed Disclaimer

References

    1. Joint United Nations Programme on HIV/AIDS (UNAIDS) Global Report: UNAIDS report on the global AIDS epidemic 2013. Geneva, Switzerland: UNAIDS; 2013.
    1. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–74. - PMC - PubMed
    1. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–22. - PMC - PubMed
    1. Marrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, Nakabilito C, et al. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtriciabine, or vaginal tenofovir gel in the VOICE study (MTN 003); Conference on Retroviruses and Opportunistic Infections (CROI); 2013 Mar 3–6; Atlanta, GA.
    1. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99. - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources